Progyny Q4 revenue rises 6.7%, beats expectations

Progyny

26/02/2026 21:13

Overview

Women's health solutions firm's Q4 revenue up 6.7%, beating analyst expectations

Adjusted EBITDA for Q4 increased 8.2%, beating analyst estimates

Company repurchased 6.5 mln shares, returning $160 mln to shareholders

Outlook

Progyny projects 2026 revenue between $1.355 bln and $1.405 bln

Company expects 2026 net income of $95.4 mln to $106.1 mln

Progyny anticipates first-quarter 2026 revenue of $319 mln to $332 mln

Result Drivers

FERTILITY SERVICES - Fertility benefit services revenue increased 11% from Q4 2024

MARGIN IMPROVEMENT - Gross margin rose to 24.1% due to efficiencies in care management services

Company press release: ID:nGNXbX6bf1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$318.40 mln
$307.45 mln (10 Analysts)
Q4 EPS
$0.14
Q4 Net Income
$12.49 mln
Q4 Adjusted EBITDA
Beat
$51.39 mln
$48.56 mln (10 Analysts)
Q4 Gross Profit
$76.88 mln
Q4 Pretax Profit
$17.85 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the managed healthcare peer group is "buy"

Wall Street's median 12-month price target for Progyny Inc is $30.00, about 40.6% above its February 25 closing price of $21.33

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)